ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовости
Деривативы
TraderScreen

Basilea Pharmaceutica AG BASILEA .../  CH0011432447  /

London International
24.05.2024  16:57:06 Изменение - Объем сделки Бид6:00:06 Предложение6:00:06 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
43.65CHF - 604
Оборот: 1,788.45		 -Величина цены спроса: - -Величина цены предложения: - 523.99 млнCHF - 45.98
GlobeNewswire 27.08 European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire 21.08 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 13.08 Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire 25.07 Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOL...
GlobeNewswire 20.06 Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Newsfile Corp 18.06 GNQ Insilico's AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated ...
GlobeNewswire 02.06 Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT...
GlobeNewswire 28.05 NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire 22.05 Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
GlobeNewswire 21.05 Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipelin...
GlobeNewswire 16.05 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 14.05 NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 f...
GlobeNewswire 03.05 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire 24.04 NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
GlobeNewswire 24.04 Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire 17.04 Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
GlobeNewswire 09.04 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire 04.04 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire 02.04 Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for t...
GlobeNewswire 11.03 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire 13.02 Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
GlobeNewswire 13.02 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire 29.01 Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Pha...
GlobeNewswire 19.01 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire 15.01 Basilea announces acquisition of preclinical antibiotics program from Spexis